ARVN Q4 2020 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-54.7% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$43M-1948.6% margin

Net Income

-$42M-1873.4% margin

EPS (Diluted)

$-0.99

QoQ Revenue Growth

-70.8%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$31M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$717M

Total Liabilities

$75M

Stockholders' Equity

$642M

Cash & Equivalents

$588M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$5M	-54.7%
Gross Profit	$2M	$5M	-54.7%
Operating Income	-$43M	-$23M	-89.6%
Net Income	-$42M	-$21M	-97.4%